RKVTF (Rakovina Therapeutics) Cash And Cash Equivalents : $0.92 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Cash And Cash Equivalents?

Rakovina Therapeutics's quarterly cash and cash equivalents declined from Jun. 2024 ($1.01 Mil) to Sep. 2024 ($0.19 Mil) but then increased from Sep. 2024 ($0.19 Mil) to Dec. 2024 ($0.92 Mil).

Rakovina Therapeutics's annual cash and cash equivalents declined from Dec. 2022 ($0.66 Mil) to Dec. 2023 ($0.33 Mil) but then increased from Dec. 2023 ($0.33 Mil) to Dec. 2024 ($0.92 Mil).

Rakovina Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Rakovina Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Cash And Cash Equivalents Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

2.20

0.66

0.33

0.92

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial											0.33	0.13	1.01	0.19	0.92

Rakovina Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Rakovina Therapeutics (OTCPK:RKVTF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Rakovina Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

7JO:Germany RKV:Canada

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.